全文获取类型
收费全文 | 5458篇 |
免费 | 326篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 83篇 |
妇产科学 | 115篇 |
基础医学 | 744篇 |
口腔科学 | 364篇 |
临床医学 | 393篇 |
内科学 | 1366篇 |
皮肤病学 | 129篇 |
神经病学 | 442篇 |
特种医学 | 129篇 |
外科学 | 806篇 |
综合类 | 20篇 |
一般理论 | 1篇 |
预防医学 | 305篇 |
眼科学 | 224篇 |
药学 | 271篇 |
中国医学 | 24篇 |
肿瘤学 | 344篇 |
出版年
2024年 | 7篇 |
2023年 | 52篇 |
2022年 | 125篇 |
2021年 | 283篇 |
2020年 | 163篇 |
2019年 | 229篇 |
2018年 | 242篇 |
2017年 | 162篇 |
2016年 | 177篇 |
2015年 | 221篇 |
2014年 | 301篇 |
2013年 | 313篇 |
2012年 | 451篇 |
2011年 | 521篇 |
2010年 | 255篇 |
2009年 | 197篇 |
2008年 | 311篇 |
2007年 | 339篇 |
2006年 | 291篇 |
2005年 | 271篇 |
2004年 | 217篇 |
2003年 | 192篇 |
2002年 | 163篇 |
2001年 | 32篇 |
2000年 | 26篇 |
1999年 | 28篇 |
1998年 | 14篇 |
1997年 | 20篇 |
1996年 | 17篇 |
1995年 | 9篇 |
1994年 | 15篇 |
1993年 | 12篇 |
1992年 | 9篇 |
1991年 | 19篇 |
1990年 | 7篇 |
1989年 | 9篇 |
1988年 | 9篇 |
1987年 | 8篇 |
1986年 | 6篇 |
1985年 | 11篇 |
1984年 | 9篇 |
1983年 | 6篇 |
1982年 | 4篇 |
1981年 | 7篇 |
1975年 | 8篇 |
1974年 | 6篇 |
1973年 | 4篇 |
1971年 | 4篇 |
1970年 | 5篇 |
1961年 | 3篇 |
排序方式: 共有5814条查询结果,搜索用时 31 毫秒
91.
92.
Mateos MV Hernández JM Hernández MT Gutiérrez NC Palomera L Fuertes M Garcia-Sanchez P Lahuerta JJ de la Rubia J Terol MJ Sureda A Bargay J Ribas P Alegre A de Arriba F Oriol A Carrera D García-Laraña J García-Sanz R Bladé J Prósper F Mateo G Esseltine DL van de Velde H San Miguel JF 《Haematologica》2008,93(4):560-565
93.
Martínez E Milinkovic A de Lazzari E Ravasi G Blanco JL Larrousse M Mallolas J García F Miró JM Gatell JM 《Lancet》2004,364(9428):65-67
The rise in didanosine concentrations in plasma when given with tenofovir raises concern for a high risk of toxic effects. Recommendations to reduce didanosine dose have been issued, but only for adults weighing more than 60 kg. We reviewed cases of pancreatitis in patients receiving didanosine plus tenofovir, didanosine alone, and tenofovir alone to assess the incidence of and risk factors for pancreatitis. Between Aug 1, 2001, and Nov 30, 2003, five of 185 (2.7%) patients receiving didanosine plus tenofovir, one of 182 (0.5%) on didanosine without tenofovir, and none of 208 on tenofovir without didanosine developed pancreatitis (p=0.016). Co-administration of both drugs versus each of them individually was an independent risk factor for pancreatitis (crude hazard ratio 10.666, 95% CI 1.246-91.294, p=0.031). These results suggest that the risk of pancreatitis is heightened when didanosine and tenofovir are given together. 相似文献
94.
Ritter C Andrades M Moreira JC Dal-Pizzol F Hussain SN 《American journal of respiratory and critical care medicine》2003,167(3):474; author reply 474-474; author reply 475
95.
José Wellington Alves dos Santos Fabiani Palagi Machado Felipe Schaich Douglas Zaione Nascimento Tiago Teixeira Simon Luis Fernando Cibin Keli Cristina Mann Vinícius André Guerra Mateus Correa Marcos Ferreira Gazzoni Marta Pires da Rocha Melissa Daubermann Falster Ronaldo Manfredini Vassoler 《Respiratory Medicine Extra》2007,3(4):186-188
96.
Sabrina F. Lisboa Felipe V. Gomes Andréia L. Silva Daniela L. Uliana Laura H. A. Camargo Francisco S. Guimar?es Fernando Q. Cunha Samia R. L. Joca Leonardo B. M. Resstel 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2015,18(8)
Background:
Inducible or neuronal nitric oxide synthase gene deletion increases or decreases anxiety-like behavior in mice, respectively. Since nitric oxide and endocannabinoids interact to modulate defensive behavior, the former effect could involve a compensatory increase in basal brain nitric oxide synthase activity and/or changes in the endocannabinoid system. Thus, we investigated the expression and extinction of contextual fear conditioning of inducible nitric oxide knockout mice and possible involvement of endocannabinoids in these responses.Methods:
We evaluated the effects of a preferential neuronal nitric oxide synthase inhibitor, 7-nitroindazol, nitric oxide synthase activity, and mRNA changes of nitrergic and endocannabinoid systems components in the medial prefrontal cortex and hippocampus of wild-type and knockout mice. The effects of URB597, an inhibitor of the fatty acid amide hydrolase enzyme, which metabolizes the endocannabinoid anandamide, WIN55,212-2, a nonselective cannabinoid agonist, and AM281, a selective CB1 antagonist, on contextual fear conditioning were also evaluated.Results:
Contextual fear conditioning expression was similar in wild-type and knockout mice, but the latter presented extinction deficits and increased basal nitric oxide synthase activity in the medial prefrontal cortex. 7-Nitroindazol decreased fear expression and facilitated extinction in wild-type and knockout mice. URB597 decreased fear expression in wild-type and facilitated extinction in knockout mice, whereas WIN55,212-2 and AM281 increased it in wild-type mice. Nonconditioned knockout mice showed changes in the mRNA expression of nitrergic and endocannabinoid system components in the medial prefrontal cortex and hippocampus that were modified by fear conditioning.Conclusion:
These data reinforce the involvement of the nitric oxide and endocannabinoids (anandamide) in stress-related disorders and point to a deregulation of the endocannabinoid system in situations where nitric oxide signaling is increased. 相似文献97.
Felipe V. Gomes Ana Carolina Issy Frederico R. Ferreira Maria-Paz Viveros Elaine A. Del Bel Francisco S. Guimar?es 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2015,18(5)
Background:
Preclinical and clinical data suggest that cannabidiol (CBD), a major non-psychotomimetic compound from Cannabis sativa, induces antipsychotic-like effects. However, the antipsychotic properties of repeated CBD treatment have been poorly investigated. Behavioral changes induced by repeated treatment with glutamate N-methyl-D-aspartate receptor (NMDAR) antagonists have been proposed as an animal model of schizophrenia-like signs. In the present study, we evaluated if repeated treatment with CBD would attenuate the behavioral and molecular modifications induced by chronic administration of one of these antagonists, MK-801.Methods:
Male C57BL/6J mice received daily i.p. injections of MK-801 (0.1, 0.5, or 1mg/kg) for 14, 21, or 28 days. Twenty-four hours after the last injection, animals were submitted to the prepulse inhibition (PPI) test. After that, we investigated if repeated treatment with CBD (15, 30, and 60mg/kg) would attenuate the PPI impairment induced by chronic treatment with MK-801 (1mg/kg; 28 days). CBD treatment began on the 6th day after the start of MK-801 administration and continued until the end of the treatment. Immediately after the PPI, the mice brains were removed and processed to evaluate the molecular changes. We measured changes in FosB/ΔFosB and parvalbumin (PV) expression, a marker of neuronal activity and a calcium-binding protein expressed in a subclass of GABAergic interneurons, respectively. Changes in mRNA expression of the NMDAR GluN1 subunit gene (GRN1) were also evaluated. CBD effects were compared to those induced by the atypical antipsychotic clozapine.Results:
MK-801 administration at the dose of 1mg/kg for 28 days impaired PPI responses. Chronic treatment with CBD (30 and 60mg/kg) attenuated PPI impairment. MK-801 treatment increased FosB/ΔFosB expression and decreased PV expression in the medial prefrontal cortex. A decreased mRNA level of GRN1 in the hippocampus was also observed. All the molecular changes were attenuated by CBD. CBD by itself did not induce any effect. Moreover, CBD effects were similar to those induced by repeated clozapine treatment.Conclusions:
These results indicate that repeated treatment with CBD, similar to clozapine, reverses the psychotomimetic-like effects and attenuates molecular changes observed after chronic administration of an NMDAR antagonist. These data support the view that CBD may have antipsychotic properties. 相似文献98.
99.
100.
Sugimoto Y Nishii K Sakakura M Araki H Usui E Lorenzo V F Hoshino N Miyashita H Ohishi K Katayama N Shiku H 《The hematology journal : the official journal of the European Haematology Association / EHA》2004,5(1):84-89
We report a 31-year-old female with t(8;21)(q22;q22) acute myeloid leukemia (AML), M2 in the FAB classification. Complete remission was achieved with daunorubicin and cytarabine induction therapy followed by three courses of high-dose cytarabine consolidation. Only 3 months later, the patient relapsed with granulocytic sarcomas (GSs) in her rhinopharynx, external acoustic meatus, and bone marrow. She received focal radiation for the GSs and successfully underwent reinduction chemotherapy. Subsequently, she received a matched related donor peripheral blood stem cell transplantation followed by high-dose chemotherapy and is now in a second remission. We summarized 79 reported cases of t(8;21) AML with GS and reviewed the literature to identify differences in the characteristics of t(8;21) AML with GS between adults and children. To our knowledge, this is the first report of pharyngeal GS in t(8;21) AML, and focal irradiation plus more intensive postinduction therapy during first remission, such as allogeneic-SCT, may be effective in adult t(8;21) AML patients with GS. 相似文献